In general, it’s wise to maintain only small positions in biopharmaceutical stocks as they can be volatile. Even if you agree with Aschoff’s assessment of Ameluz’s clinical data and revenue-generating potential, caution is still advised.Īnd, let’s just see if the stock can get back to $10 first, before eyeing $20. It’s probably best to start with a small long position in BFRI stock. This $20 price target is just one analyst’s prediction. That’s a fair assessment, but investors need to be realistic. Moreover, the analyst evidently views Ameluz’s clinical data as superior to its peers. In early December, that represented a multi-bagger return on investment.Īpparently, Aschoff analyst believes that Biofrontera will “meaningfully increase” its Ameluz revenue in actinic keratosis as it substantially increases its U.S. Reportedly, Roth Capital analyst Jonathan Aschoff initiated his coverage of Biofrontera with a “buy” rating and $20 price target. Rather, the catalyst was an ambitious price target set by a prominent Wall Street expert. Yet, interestingly enough, it’s not what caused BFRI stock to jump recently. The patent-related news is significant for Biofrontera. Lübbert added that, “Patent protection on either part of the FDA-combination approval increases our competitive advantage and is likely to hinder generic competition in the US market.” A Path to $20? With that, Biofrontera should be better positioned to solidify its niche-market foothold. And in fact, that’s what Biofrontera’s wholly owned subsidiary, Biofrontera Pharma GmbH, recently did.Īccording to a press release, the subsidiary “received a notice of allowance from the United States Patent and Trademark office (USPTO) with respect to the patent application “Illumination for Photodynamic Therapy.”īiofrontera CEO Hermann Lübbert explained that this event “is an important part of Biofrontera’s patent strategy to further protect” Ameluz together with BF-RhodoLED and its successor model, RhodoLED XL, in the U.S. patents covering its high-conviction products like Ameluz and BF-RhodoLED. So, it makes sense that Biofrontera would seek U.S. It’s a smart move for an innovative company like Biofrontera to protect its intellectual property through patents. Without a doubt, $5 is going to be a key level to keep your eye on as the fierce tug-of-war between the buyers and sellers could persist for quite a while. As of today, the stock was down to $4.23. That was the short-term peak and BFRI stock was soon back on a downtrend again. Miraculously, the buyers stepped in and pushed the Biofrontera share price up to $10.40 on Nov. It wasn’t an auspicious start, and the situation only got worse as BFRI stock slid to $2.50 - literally getting cut in half by Nov. Then, later that month, the company settled on an IPO price of $5 per share. In early October, Biofrontera established a price range for its initial public offering (IPO) between $5 and $7.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |